Read Time: 5 mins

Back to the Future – Has Medical Treatment of Glaucoma Improved?

Copy Link
Published Online: Dec 23rd 2015 European Ophthalmic Review, 2015;9(2):132–7 DOI:
Authors: Carlo E Traverso, Norbert Pfeiffer, Gábor Holló, Lutz Pillunat
Quick Links:
Article Information

These proceedings are based on a symposium that were presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015. The symposium was arranged to bring together leaders in ophthalmology to explore advances in the medical treatment of glaucoma. Many patients with glaucoma require combination therapy. Fixed-dose combinations represent a significant improvement in the medical treatment of glaucoma, being advantageous in terms of their association with good compliance and elimination of the wash-out effect. While preservatives are a historic necessity, their use is associated with increased ocular surface disease and higher indirect cost. The novel preservative-free tafluprost/timolol fixed-dose combination provides mean diurnal intraocular pressure (IOP) lowering of up to 40 % from baseline and demonstrates similar efficacy with other prostaglandin/timolol fixed-dose combinations, is superior to its individual components and non-inferior to its individual components given concomitantly. The tafluprost/timolol fixed-dose combination is well-tolerated with low prevalence of hyperaemia. It is generally accepted that function loss follows structural damage and that normal-pressure glaucoma (NPG) and high-pressure glaucoma (HPG) represent that same disease, separated by an arbitrary pressure level. However, functional damage (pattern electroretinogram) is detectable prior to structural damage and NPG patients show less retinal nerve fibre layer and visual field loss compared with the same optic nerve head morphology HPG patients. NPG patients seem to lose connective tissue first whereas, in HPG, patients seem to lose retinal nerve fibres first. Thus, whether NPG and HPG are the same disease is an open question.


Fixed-dose combinations, glaucoma, preservative free, tafluprost/timolol, high-pressure glaucoma (HPG), normal-pressure glaucoma (NPG)


Proceedings of a Symposium Presented at the
European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015

New medical formulations for the treatment of glaucoma are likely to improve outcomes for patients. A novel preservative-free tafluprost/timolol fixed-dose combination has been shown, in clinical trials, to effectively lower intraocular pressure (IOP) and appears to be well tolerated. A satellite symposium was held at the European Society of Ophthalmology (SOE) congress in Vienna, Austria on the 8 June 2015 to look to the future and ask: has medical treatment of glaucoma improved?

The Role of Preservative-free Medications and Fixed-dose Combinations in the Treatment of Glaucoma
In treating glaucoma, the dual aim is to preserve vision and lower IOP; however, the mission statement of the European Glaucoma Society (EGS)1 guidelines states an additional concern: “The goal of treatment is to maintain patients’ visual function and related quality of life… .” Thus, for the patient, quality of life in addition to IOP control is crucial. The EGS has published a scheme to show that target IOP depends on a series of factors that must all be treated as a whole (see Figure 1A). Included are glaucoma damage, life expectancy, additional risk factors (e.g. pseudo-exfoliation), untreated IOP and rate of progression.

Prostaglandin mono preparations reduce IOP effectively in patents with open-angle glaucoma (OAG) or ocular hypertension, bringing mean IOP down, e.g. from around 26 mmHg at baseline to approximately 17 mmHg at week 12.2 However, a significant number of glaucoma patients need more than one medication. In the Ocular Hypertension Treatment Study, 40 % of patients were being treated with two or more medications after 5 years.3 Yet adding two or more medications can reduce compliance significantly.4 Besides a decrease in the percentage of patients who are compliant, other potential problems can develop with patients on multiple medications. Although patients are asked to wait a minimum of 5 minutes between dosing different medications to eliminate the potential to washout the first medication, not all patients will actually do this, reducing the potential treatment benefit. If a patient waits only 30 seconds, for example, only around half of the first drug is adsorbed.5 This underscores the role of fixed-dose combinations. Therefore, when administering adjunctive therapy, one additional agent, from a different class, can be added to initial monotherapy.1 It is advantageous to facilitate compliance by both minimising the number of drops and dosing frequency and using fixed-dose combinations if possible. When adjusting target IOP, the EGS has devised a useful flow chart that includes consideration of side effects, compliance, quality of life and the ocular surface (see Figure 1B).

Ocular surface disease is an umbrella term that includes dry eye disease (as assessed by Schirmer’s test, break-up time, etc.), red eye, ocular discomfort, as characterised by itching, burning and foreign body sensation as well as allergy. Ocular surface disease is more frequent in patients with glaucoma.6 Quality of life declines with the increasing severity of dry eye disease7 and compliance presumably decreases as patients notice problems associated with their eye drops. In a crosssectional study, using the Ocular Surface Disease Index for measuring symptoms of dry eye, 59 % of 101 patients reported symptoms in at least one eye; Schirmer’s testing showed 61 % of glaucoma patients with a decrease in tear production in at least one eye and corneal and conjunctival lissamine green staining showed positive results in 22 % of patients whereas tear break-up time was decreased in 78 %.8Furthermore, benzalkonium chloride (BAK)-containing drops were associated with higher odds of showing abnormal results on the

lissamine green staining test (odds ratio = 2.03; 95 % confidence interval [CI] 1.06–3.89; p=0.034). In The German Glaucoma and Dry Eye Register (20,506 patients; 900 centres),6 more women were found to develop dry eye and glaucoma than men (56.9 % versus 45.7 %, respectively). Dry eye occurred with dissimilar frequencies in association with the various glaucoma types: pseudo-exfoliation > primary OAG > pigmentary glaucoma. Dry eye occurred more frequently when three or more anti-glaucoma drugs were used and increased with the duration of glaucoma and the use of preservatives.6

• A large number of glaucoma patients need combination therapy.
• Fixed-dose combinations are advantageous owing to improved compliance and elimination of the wash-out effect.
• Preservatives in glaucoma medications increase the prevalence of ocular surface disease.

Novel Preservative-free Fixed-dose Combination of Tafluprost and Timolol
Preservative-free fixed-dose combination of 0.0015 % tafluprost and 0.5 % timolol maleate has received regulatory approval in Europe.9 At the time of the symposium it was available in Germany, the Nordic countries and the UK and there were plans for its introduction in other EU countries in 2015.

Superiority Study of Fixed-dose Combination versus its Components
A stratified, double-masked, randomised, multicentre phase III study was conducted to compare efficacy, safety and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015 % and timolol 0.5 % (Taptiqom®) to those of the individual components.10 Patients had to be on prior prostaglandin/timolol 0.5 % therapy for at least 2 weeks before screening and needed to have an IOP of 20 mmHg (prostaglandin) or 22 mmHg (timolol) and after run-in, washout and then study treatment for 6 months. Patients had OAG or ocular hypertension inadequately controlled on prior timolol (n=189) or prostaglandin (n=375) monotherapy. Included were patients with OAG or ocular hypertension inadequately controlled on prior timolol (n=189) or prostaglandin (n=375) monotherapy. Patients in both these groups received for 6 months either: preservative-free fixed-dose combination of tafluprost 0.0015 % and timolol 0.5 % (Taptiqom®), once daily; preservative-free tafluprost 0.0015 %, once daily; or preservative-free timolol 0.5. %, twice daily (see Figure 2). Study visits after baseline were performed at 2 and 6 weeks, 3 and 6 months and at a post-study visit. IOP was measured at 8 am, 10 am, 4 pm and 8 pm. The mean IOP changes at month 3 showed superiority of the fixed-dose combination over tafluprost (see Figure 3A) and timolol (see Figure 3B) monotherapy; superiority was statistically significant in both strata (p<0.05; see Table 1). The frequency of treatment-related conjunctival hyperaemia of the fixed-dose combination was low in both strata: 4.8 % and 9.5 % for the prostaglandin stratum and timolol stratum, respectively, and 6.4 % over the two strata. In both strata, the mean severity of conjunctival hyperaemia, evaluated by reference photographs, peaked at week 2 and then showed a downward trend during the course of the study.

Non-inferiority Study of Fixed-dose Combination versus Concomitant Use of its Components
To compare efficacy, safety and tolerability of the preservative-free fixed-dose combination and non-fixed combination of tafluprost 0.0015 % and timolol 0.5 %, a non-inferiority study was conducted.11 This was a prospective, randomised, double-masked, activecontrolled, parallel group, multicentre phase III study including 400 patients with ocular hypertension and OAG, pseudo-exfoliative and pigmentary glaucoma with an IOP ≥23 mmHg in at least one eye at 8 am at baseline and ≤36 mm in both eyes at any timepoint at screening. Patients received for 6 months either: a preservativefree fixed-dose combination of tafluprost 0.0015 %/timolol 0.5 % (Taptiqom®) once daily, or preservative-free tafluprost 0.0015 % once daily and preservative-free timolol 0.5 % twice daily as a nonfixed combination. A comparison of mean time-wise IOP decreases, which ranged from –7.3 to –9.1 mmHg (29.6–34.6 %) in the fixed-dose combination arm, and from –7.5 to –9.4 mmHg (30.7–36.0 %) in the non-fixed combination arm, indicated that the fixed-dose combination therapy was equally as effective as the non-fixed combination (see

Figure 4).11 According to the set non-inferiority criterion of a primary efficacy endpoint, this was based on the change from baseline in the average diurnal IOP (treatment difference of the groups) at 6 months, and not on the timewise decreases, although these also proved to be non-inferior. The equivalent efficacy between the fixed-dose and non-fixed combination arms was achieved despite a lesser degree of timolol exposure in the non-fixed arm (once-daily, preservative-free, fixed-dose combination). Conjunctival/ocular hyperaemia was the most common treatment-related adverse event and was found in 8 % of patients in the fixed-dose combination arm and 5 % of patients in the non-fixed combination arm. The severity of hyperaemia was comparable in both treatment arms (mean change from baseline of approximately 0.2 on a 0–4 scale). The mean change of severity score was highest at week 2 and declined thereafter.

Tafluprost/Timolol Fixed-dose Combinations in Comparison with Other Prostaglandin/ Timolol Combinations
To review the performance of preservative-free tafluprost/timolol fixeddose combination in glaucoma with that of the other prostaglandin– timolol fixed-combination products on the market, 16 published double-masked, controlled phase III clinical trials with the four fixedcombination products latanoprost/timolol, bimatoprost/timolol, travoprost/timolol and tafluprost/timolol have been analysed.12 Only double-masked studies with a washout of previous IOP-lowering medication before the initiation of the treatment with the combination product were selected. The scatter plot showing the mean IOP changes at 3 months versus mean baseline IOP for the fixed prostaglandin-timolol combination products are presented in Figure 5; the mean baseline IOP appeared to predominantly determine the magnitude of the IOP reduction. The IOP reduction with tafluprost/timolol was similar to that of other prostaglandin–timolol fixed combination productions. With the tafluprost/timolol fixed-dose combination, the IOP reduction from untreated baseline was between 28–40 %. Further, the IOP reduction with tafluprost/timolol fixed-dose combination is similar to other fixeddose combinations based on authority-approved labelling.13–15

Safety and Tolerability of the Tafluprost/Timolol Fixed-dose Combination
In a review summarising safety and tolerability of the preservative-free 0.0015 % tafluprost/0.5 % timolol fixed-dose combination, the fixed

combination demonstrated improved tolerability compared with other combinations of the prostaglandin analogue/timolol class.16 Conjunctival hyperaemia, which was the most common side effect, was mild in severity and occurred in only 6.4–8 % of patients during 6 months of treatment (see Table 2). Figures for ocular irritation were likewise low (7.0–12.7 %). Furthermore, the fixed-dose combination of tafluprost 0.0015 % and timolol 0.5 % has been shown to provide a significant IOP reduction in pseudo-exfoliative glaucoma.17 Mean time-wise IOP fell by 8.62 to 10.25 mmHg (31.8 to 36.7 %) in the fixed-dose combination arm (15 patients) and by 5.38 to 11.35 mmHg (21.3 to 41.2 %) in the non-fixed combination arm (13 patients) (p<0.001 for all comparisons).

Novel preservative-free tafluprost/timolol fixed-dose combination:
• lowers IOP effectively; • is superior to its individual components;
• is non-inferior to its individual components given concomitantly;
• provides mean diurnal IOP lowering of up to 40 % from baseline at 3 months and demonstrates similar efficacy with other prostaglandin/timolol fixed-dose combinations; and
• is well-tolerated and, as a prostaglandin-containing product, is associated with a low prevalence of hyperaemia.

Structure and Function in the Diagnosis of Glaucoma
Glaucoma is characterised by chronic retinal ganglion cell (RGC) damage that is not detected by automated perimetry until between 25 and 35 % of the RGCs have been lost.18 Another tool would therefore be useful to identify glaucoma in patients with suspicious optic nerve morphology or high IOP. The pattern electroretinogram (PERG) directly reflects RGC function.19 A longitudinal study of 64 glaucoma suspects with ocular hypertension was performed.19 PERG, in particular the PERG ratio, detected conversion of these patients to a diagnosis of glaucoma patients 4 years before apparent visual field changes. Over the course of this study, 13 eyes converted to glaucoma (mean followup 10.3 years); PERG ratio, peak time and amplitude were significantly lower in converters. In patients who are glaucoma suspects, PERG signal appears to anticipate an equivalent loss of the optical coherence tomography signal by several years.20 The time lag between PERG amplitude and retinal nerve fibre layer (RNFL) thickness to lose 10 % of their initial values is in the order of 8 years. Estimates suggested that the PERG amplitude takes 1.9 to 2.5 years to lose 10 % of its initial amplitude, whereas the RNFL thickness takes 9.9 to 10.4 years to lose 10 % of its initial thickness. Thus, functional damage can be detected before any structural damage occurs.

Often, more advanced optic nerve damage is observed clinically in NPG compared with HPG is observed clinically. This represents a discrepancy with the view of NPG and HPG as essentially being the same disease. Graefe pointed out in 1850 that optic disc nerve damage could be observed in the absence of any IOP elevation. To examine differences in function, the morphology has to be identical; conversely, to examine differences in morphology, the function has to be identical. Due to variations and the psychophysiological background, visual fields are often difficult to compare; therefore, optic nerve damage has to be similar (including optic disc size). With equal levels of glaucoma-based structural damage of the optic nerve head indicated by cupping, rim area and rim volume, NPG patients seem to have a less-affected visual field and a better preserved nerve fibre layer than HPG patients.21 This was a retrospective, pairmatched, comparative study that included 126 patients with NPG and 126 patients with HPG. Based on the Heidelberg Retina Tomograph, NPG and HPG patients showed comparable structural damage of the optic nerve head without a statistically significant difference between both groups (mean, NTG/HPG: disc area 2.32/2.32 mm²; p=0.342; rim area 1.03/1.00 mm²; p=0.279; rim volume 0.2/0.19 mm³; p=0.274).

Thus, the questions arise as to whether NPG patients lose predominantely connective tissue first, whether NPG and HTG really are the same disease, why do HTG patients show earlier and more pronounced visual field loss and whether this is due to the effects of IOP or an aspect of biomechanics.

• Functional damage (PERG) can be detected before any structural damage occurs.
• NPG patients show less visual field loss and less RNFL compared with same optic nerve head morphology HPG patients.
• NPG patients seem to lose connective tissue first whereas HPG patients seem to lose retinal nerve fibres first.

Conclusions and Future Directions
A preservative-free fixed-dose combination of 0.0015 % tafluprost and 0.5 % timolol maleate is now available for the treatment of glaucoma, which has shown in clinical trials to be effective and well tolerated with a low prevalence of hyperaemia. In addition to this improvement in the medical treatment of glaucoma, electrophysiological techniques are also improving. With methodological advances, an objective test may become available for the early diagnosis of glaucoma and allow for its prompt treatment.

Article Information:

Carlo E Traverso has received grants from Alcon, Allergan, Santen and Théa. Norbert Pfeiffer has received research grants from Santen, Alcon, Novartis and Allergan and speakers’ honoraria from Santen, Alcon and Allergan. Gábor Holló is a Consultant for Alcon and Santen. Lutz E Pillunat has received lecture fees from Allergan and Santen and is on the Advisory Board for Allergan and Santen, and received grant support from Novartis.


Carlo E Traverso, Clinica Oculistica, V. le Benedetto XV, 5 – 16132, Genova, Italy. E:


These symposia proceedings and the symposium itself have been produced and paid for by Santen. The views and opinions expressed are those of the authors and not necessarily those of Santen. This article reports the proceedings of a sponsored satellite symposium held at the European Society of Ophthalmology 2015 Congress and as such has not been subject to the journals usual peer-review process. The report was reviewed for scientific accuracy by the symposium chairman before publication.


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.


Editorial assistance was provided by Catherine Amey at Touch Medical Media and funded by Santen.




1. European Glaucoma Society (EGS) Guidelines. Terminology and guidelines for glaucoma (4th edition) 2014. Available at: (accessed 24 June 2015).
2. Parrish RK, Palmberg P, Sheu WP, A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study, Am J Ophthalmol, 2003;135:688–703.
3. Kass MA, Heuer DK, Higginbotham EJ, et al., The OcularHypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma, Arch Ophthalmol, 2002;120:701–13; discussion 829–30.
4. Patel SC, Spaeth GL, Compliance in patients prescribed eyedrops for glaucoma, Ophthalmic Surg, 1995;26:233–6.
5. Chrai SS, Makoid MC, Eriksen SP, Robinson JR, Drop size and initial dosing frequency problems of topically applied ophthalmic drugs, J Pharm Sci, 1974;63:333–8.
6. Erb C, Gast U, Schremmer D, German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye, Graefes Arch Clin Exp Ophthalmol, 2008;246:1593–601.
7. Rossi GC, Tinelli C, Pasinetti GM,et al., Dry eye syndromerelated quality of life in glaucoma patients, Eur J Ophthalmol, 2009;19:572–9.
8. Leung EW, Medeiros FA, Weinreb RN, Prevalence of ocular surface disease in glaucoma patients, J Glaucoma, 2008;17:350–5.
9. Santen Announces Positive Outcome of the European Decentralized Procedure for Approval of TAPTIQOM® [press release]. 10/22/2014 2014.
10. Pfeiffer N, Traverso CE, Lorenz K, et al., A 6-month study comparing efficacy, safety, and tolerability of the preservativefree fixed combination of tafluprost 0.0015 % and timolol 0.5 % versus each of its individual preservative-free components, Adv Ther, 2014;31:1228–46.
11. Hollo G, Hommer A, Anton Lopez A, Ropo A, Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015 %/timolol 0.5 % versus concomitant use of the ingredients, J Ocul Pharmacol Ther, 2014;30:468–75.
12. Hollo G, Vuorinen J, Tuominen J, et al., Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products, Adv Ther, 2014;31:932–44.
13. Summary of Product Characteristics. TAPTIQOM 15 MICROGRAMS/ML + 5 MG/ML EYE DROPS SOLUTION IN SINGLE-DOSE CONTAINER. Available from: http://www. %2015 %20 MICROGRAMS/ML %20//// %205 %20MG/ML %20EYE %20 DROPS %20 %20SOLUTION %20IN %20SINGLE-DOSE %20CO NTAINER&subsName=TAFLUPROST&pageID=SecondLevel (accessed 24 June 2015).
14. Summary of Product Characteristics. DuoTrav eye drops solution 2015. Available from: emc/medicine/17774 (accessed 24 June 2015).
15. European Medicines Agency. European public assessment reports. GANFORT 2013. Available from: http://www.ema. medicines/000668/human_med_000804.jsp&mid=WC0b 01ac058001d125&murl=menus/medicines/medicines.jsp (accessed 24 June 2015).
16. Hollo G, Katsanos A, Safety and tolerability of the tafluprost/ timolol fixed combination for the treatment of glaucoma, Expert Opin Drug Saf, 2015;14:609–17.
17. Hollo G, Ropo A, Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma, Curr Med Res Opin, 2015;31:13–6.
18. Kerrigan DF, Mitchell RS, Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons, Invest Ophthalmol Vis Sci, 2000;41:741–8.
19. Bode SF, Jehle T, Bach M, Pattern electroretinogram in glaucoma suspects: new findings from a longitudinal study, Invest Ophthalmol Vis Sci, 2011;52:4300–6.
20. Banitt MR, Ventura LM, Feuer WJ, et al. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects, Invest Ophthalmol Vis Sci, 2013;54:2346–52.
21. Hantzschel J, Terai N, Sorgenfrei F, et al.,Morphological and functional differences between normal-tension and hightension glaucoma, Acta Ophthal, 2013;91:e386–91.

Further Resources

Share this Article
Related Content In Glaucoma
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72